Inositol polyphosphate 5-phosphatase OCRL

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 21: Line 21:
Lowe syndrome is inherited in an X-linked manner. About two-thirds of cases are transmitted by maternal carriers. Affected males are not known to reproduce. Female carriers show heterozygous female phenotype, which might indicate the need for genetic counseling. The remaining one third (approximately) is attributed to a de novo variant. There is a high risk (4,5%) of germline mosaicism in Lowe syndrome families. If OCRL pathogenic variant has been identified in a family member, prenatal genetic testing can be performed. Unfortunately, it can not say anything about the severity of the disease. <ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/><ref name="Evidence"/>
Lowe syndrome is inherited in an X-linked manner. About two-thirds of cases are transmitted by maternal carriers. Affected males are not known to reproduce. Female carriers show heterozygous female phenotype, which might indicate the need for genetic counseling. The remaining one third (approximately) is attributed to a de novo variant. There is a high risk (4,5%) of germline mosaicism in Lowe syndrome families. If OCRL pathogenic variant has been identified in a family member, prenatal genetic testing can be performed. Unfortunately, it can not say anything about the severity of the disease. <ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/><ref name="Evidence"/>
-
Treatment is only symptomatic. Patients usually require more than one medical specialist to manage various clinical problems.<ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/><ref name="Evidence"/ref> Regular surveillance by many specialists is also needed in many fields for the whole lifetime. <ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/>
+
Treatment is only symptomatic. Patients usually require more than one medical specialist to manage various clinical problems.<ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/><ref name="Evidence"/> Regular surveillance by many specialists is also needed in many fields for the whole lifetime. <ref name="Lowe syndrome"/><ref name="Oculocerebrorenal"/>
== Structural highlights ==
== Structural highlights ==

Revision as of 07:00, 28 April 2021

OCRL-1 mutations causing Lowe syndrome

Caption for this structure

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 Lewis RA, Nussbaum RL, Brewer ED. Lowe Syndrome PMID:20301653
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Bokenkamp A, Ludwig M. The oculocerebrorenal syndrome of Lowe: an update. Pediatr Nephrol. 2016 Dec;31(12):2201-2212. doi: 10.1007/s00467-016-3343-3. Epub , 2016 Mar 24. PMID:27011217 doi:http://dx.doi.org/10.1007/s00467-016-3343-3
  3. 3.0 3.1 3.2 Kenworthy L, Charnas L. Evidence for a discrete behavioral phenotype in the oculocerebrorenal syndrome of Lowe. Am J Med Genet. 1995 Nov 20;59(3):283-90. doi: 10.1002/ajmg.1320590304. PMID:8599350 doi:http://dx.doi.org/10.1002/ajmg.1320590304

Proteopedia Page Contributors and Editors (what is this?)

Alois Zdrha, Michal Harel, Jaime Prilusky

Personal tools